Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trialRaphael Schiffmann, Derralynn Hughes, Özlem Göker-Alpan et al.|Journal of Inherited Metabolic Disease|2019Cited by 137
Survey Outcome on Immunogenicity Risk Assessment Tools for Biotherapeutics: an Insight into Consensus on Methods, Application, and Utility in Drug DevelopmentJochem Gokemeijer, Sofie Pattijn, Shan Chung et al.|The AAPS Journal|2023Cited by 22